1-(4-ISOXAZOLE-5-YL)-1H-PYRAZOLE-1-YL)-2-METHYLPROPANE-2-OL DERIVATIVES AND RELATED COMPOUNDS AS IL-17 AND IFN-GAMMA INHIBITORS FOR TREATMENT OF AUTOIMMUNE DISEASES AND CHRONIC INFLAMMATION Russian patent published in 2022 - IPC C07D413/04 C07D413/14 C07D417/14 A61K31/422 A61K31/427 A61K31/5377 A61K31/541 A61P1/04 A61P5/14 A61P9/10 A61P17/06 A61P19/02 A61P37/06 

FIELD: pharmaceutical chemistry.

SUBSTANCE: group of inventions relates to pharmaceutical chemistry and includes a compound of the formula (I) and its use for the manufacture of a drug for the treatment of a disease or a medical condition, in which inhibition of interleukin-17 (hereinafter – IL-17) and/or interferon-γ (hereinafter – IFN-γ) is preferable. In the formula (I), Ar is selected from a group consisting of phenyl and pyridyl, each of which is optionally substituted with one, two, or three independently selected substitutes R^Ar; R^Ar is selected from a group consisting of halogen, -OH, -CN, C_1-6-alkoxy, di-C_1-6-alkylamino-C_1-6-alkoxy, -CONHR’, benzyloxy, -CO-azetidinyl, -CO-pyrrolidinyl, -CO-morpholinyl, -CO-C_3-6-cycloalkyl, -CONH-C_3-6-cycloalkyl, and -O-C_1-6-alkyl-heterocycle, where heterocycle is selected from a group consisting of pyrrolidinyl, piperazinyl, morpholinyl, 1,1-dioxothiomorpholinyl, and (2-oxa-6-azaspiro[3.3]hept-6-yl)-C_1-4-alkoxy, and where each of the specified heterocycle groups is optionally substituted with C_1-6-alkyl, and where R’ is C_1-6-alkyl; Z is selected from a group consisting of H, -CO-R^Z, -CH₂-O-R^Z, -CO-CH₂-R^Z, -CO-CH₂-O-R^Z, -COOR^Z, -CO-NHR^Z, -C_1-6-alkyl-O-C_1-6-alkyl-O-R^Z, C_1-6-alkyl, C_2-6-alkenyl, C_2-6-alkynyl, 5- or 6-element heteroaryl including one or two heteroatoms independently selected from N, S, and O, and tetrahydrofuranyl, where each of the specified alkyl and heteroaryl groups is optionally substituted with C_1-6-alkyl, OH, or C_3-6-cycloalkyl; R^Z is selected from a group consisting of H, C_1-6-alkyl, C_2-6-alkenyl, C_2-6-alkynyl, C_3-6-cycloalkyl, and oxetanyl; Y is C_1-4-halogenalkyl or C_1-6-alkyl; R1 is such as specified in the claims.

EFFECT: compound of the formula (I), having inhibitory activity relatively to interleukin-17 (IL-17) and/or interferon-γ (IFN-γ).

11 cl, 1 tbl, 167 ex